A novel deep learning model predicted retinal nerve fiber layer thickness from optic disc photos, enabling risk stratification for primary open-angle glaucoma in ocular hypertension patients, with baseline and longitudinal changes strongly
Deep learning models predicting RNFL thickness from optic disc photographs can identify ocular hypertension patients at higher risk for primary open-angle glaucoma, enhancing early risk assessment and monitoring disease progression.
A recent randomized clinical trial demonstrates that diversified segmental defocus optimization (DSDO) spectacle lenses significantly reduce the onset and progression of myopia in children, with or without adjunct low-dose atropine.
Low-level light therapy, administered perioperatively, significantly reduces dry eye symptoms and preserves ocular surface integrity after cataract surgery, offering a noninvasive adjunct to standard care.
The MI-SIGHT telemedicine program significantly improves vision and eye health outcomes by providing glaucoma and eye disease screening with care navigation in community health centers, demonstrating high satisfaction and cost-effectiveness
A large UK Biobank study demonstrates that poor sleep, low physical activity, and high sedentary behavior independently and jointly increase cataract risk, with lifestyle modifications reducing incidence.
A large retrospective study found that diabetic patients using metformin for at least five consecutive years have a significantly lower risk of developing age-related macular degeneration, especially the dry type.
UCLA engineers and ophthalmologists mapped segmental, task-dependent activation of the orbicularis oculi during five closure behaviors, defining a roadmap for targeted neurostimulation to restore protective blinking in patients with eyelid
Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.
The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.
Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.
GLP-1 receptor agonist use, especially liraglutide, is associated with a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION) during the first year, particularly in patients without diabetes or obesity.
Open language-specific specialty feeds and department pages.